-Executive Management to Host Conference Call on November 7, 2016 at 11:00 a.m. ET-
PR Newswire
MISSISSAUGA, Ontario, Oct. 24, 2016
MISSISSAUGA, Ontario, Oct. 24, 2016 /PRNewswire/ --Aralez
Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its third quarter 2016 financial results
on Monday, November 7, 2016, before the opening of the U.S. financial markets. Following the
announcement, executive management will host a conference call and webcast at 11:00 a.m. ET on such
date to discuss the financial results and recent highlights.
Audio Webcast/ Conference Call Details
Date: Monday, November 7, 2016
Time: 11:00 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037
A live webcast and audio archive for the event may be accessed from the Investors section of the Aralez website at www.aralez.com. Please connect to the website prior to the start of
the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of
the webcast will be archived on the website for two weeks.
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on
delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and
commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in
Mississauga, Ontario, Canada, its U.S. Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. More
information about Aralez can be found at www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
732-754-2545
nochsner@aralez.com
Logo - http://photos.prnewswire.com/prnh/20161001/414159LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aralez-to-announce-third-quarter-2016-results-on-november-7-2016-300349440.html
SOURCE Aralez Pharmaceuticals Inc.